Go Pro
NASDAQ:ACON

Aclarion Q4 2025 Earnings Report

Aclarion logo
$2.62 +0.04 (+1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$2.47 -0.15 (-5.65%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclarion EPS Results

Actual EPS
-$2.01
Consensus EPS
-$3.60
Beat/Miss
Beat by +$1.59
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.02 million
Beat/Miss
Missed by -$1.52 thousand
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Wednesday, March 18, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Aclarion's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aclarion Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile